SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Orchid Pharma shines on getting EIR from USFDA on inspection closure for Tamil Nadu plant

11 Apr 2016 Evaluate

Orchid Pharma is currently trading at Rs 41.40, up by 2.65 points or 6.84% from its previous closing of Rs. 38.75 on the BSE.

The scrip opened at Rs 39.45 and has touched a high and low of Rs 43.90 and Rs 39.45 respectively. So far 701055 shares were traded on the counter.

The BSE group 'B' stock of face value Rs 10 has touched a 52 week high of Rs 75.30 on 06-Aug-2015 and a 52 week low of Rs. 32.60 on 29-Feb-2016.

Last one week high and low of the scrip stood at Rs. 40.50 and Rs. 37.35 respectively. The current market cap of the company is Rs. 369.20 crore.

The promoters holding in the company stood at 39.92% while Institutions and Non-Institutions held 5.61% and 54.47% respectively.

Orchid Pharma has received the Establishment inspection report (EIR) from US Food and Drug Administration (USFDA) based on the successful inspection closure for the API manufacturing facility located at Alathur in Kancheepuram District, Tamil Nadu. The facility was inspected by USFDA in the month of August 2015.

Orchid Pharma is a pharmaceutical company engaged in development and manufacture of active pharmaceutical ingredients (APIs) and finished dosage forms. It is also engaged in research of new drugs.

Orchid Pharma Share Price

570.50 6.40 (1.13%)
17-Apr-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1675.20
Dr. Reddys Lab 1235.40
Cipla 1238.30
Zydus Lifesciences 942.55
Lupin 2324.25
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×